Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

Author:

Geffen N1,Aagaard P2,Corbelli GM3,Meulbroek M4,Peavy D5,Rappoport C6,Schwarze S7,Collins S8,

Affiliation:

1. Centre for Social Science Research; University of Cape Town; Cape Town South Africa

2. Centre for Health & Infectious Disease Research; Department of Infectious Diseases and Rheumatology, Rigshospitalet; University of Copenhagen; Copenhagen Denmark

3. European AIDS Treatment Group; Rome Italy

4. Projecte dels NOMS-Hispanosida; Barcelona Spain

5. Newark EMA HIV Health Services Planning Council; Newark NJ USA

6. University of California; San Francisco CA USA

7. European AIDS Treatment Group; Berlin Germany

8. HIV i-BASE; London UK

Funder

National Institute of Allergy and Infectious Diseases

NIH Clinical Center

National Cancer Institute

National Heart, Lung, and Blood Institute

National Institute of Mental Health

National Institute of Neurological Disorders and Stroke

National Institute of Arthritis and Musculoskeletal Disorders

French Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS)

German Ministry of Education and Research

European AIDS Treatment Network (NEAT)

Australian National Health and Medical Research Council

UK Medical Research Council

National Institute for Heath Research

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference27 articles.

1. UNAIDS Around 10 million people living with HIV now have access to antiretroviral treatment [Internet] http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2013/june/20130630prtreatment/

2. WHO Global update on HIV treatment 2013: results, impact and opportunities [Internet] http://www.who.int/hiv/pub/progressreports/update2013/en/

3. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK cohort study;May;AIDS,2014

4. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study;Babiker;Clin Trials,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3